Hing Sham - Global Blood Senior Vice President - Chemistry

GBTDelisted Stock  USD 68.49  0.00  0.00%   

President

Dr. Hing Sham, Ph.D. is Senior Vice President, Research of the company. He was Senior Vice President, Chemistry, from July 2014 to April 2016. Most recently, from January 2013 to July 2014, Dr. Sham served as head of research and development at iOneWorldHealthPath.org, a nonprofit pharmaceutical development organization. Prior to that, from September 2006 to November 2012, he served as senior vice president of research and head of chemical sciences at Elan Pharmaceuticals, Inc., a biopharmaceutical company, where he led the chemistry team in the discovery of two clinical candidates for the treatment of Alzheimers disease. From July 1983 to August 2006, Dr. Sham worked at Abbott Laboratories Inc., a global healthcare company, where he and his team discovered and advanced 10 clinical candidates spanning cardiovascular disease, HIV, oncology and diabetes. His 24year tenure at Abbott Laboratories culminated in his appointment as a distinguished research fellow in global pharmaceutical discovery. Dr. Sham is the coinventor of Norvir and the primary inventor of Kaletra, Abbott Laboratories first and secondgeneration HIV protease inhibitors approved for the treatment of HIV. Dr. Sham has published more than 180 scientific articles in peerreviewed journals and is a named inventor on 81 issued U.S. patents. Dr. Sham was named Hero of Chemistry by the American Chemical Society in 2003 since 2016.
Age 64
Tenure 8 years
Professional MarksPh.D
Phone650 741-7700
Webwww.globalbloodtx.com
Sham holds a Ph.D. in synthetic organic chemistry from the University of Hawaii and completed his postdoctoral training in the department of chemistry at Indiana University.

Global Blood Management Efficiency

The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Ferdinand JahnelMarsh McLennan Companies
N/A
John MicenkoUnited Homes Group
N/A
Alison RandPrimerica
56
William KellyPrimerica
65
Tsai PanTencent Music Entertainment
50
Andrew LevineSL Green Realty
65
Michael AdamsPrimerica
67
Robert PetermanPrimerica
58
Kevin BrownMI Homes
N/A
Stacy MillsMarsh McLennan Companies
59
Kathryn KieserPrimerica
51
Peter BesharMarsh McLennan Companies
58
Peter SchneiderPrimerica
68
Robert RapportMarsh McLennan Companies
N/A
Jeffrey FendlerPrimerica
67
Parimala RaoSL Green Realty
N/A
Andrew MathiasSL Green Realty
50
Norman SchmeichelICC Holdings
55
E GilbertMarsh McLennan Companies
63
Gregory PittsPrimerica
61
Michael MillerPrimerica
43
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease . Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Global Blood operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 457 people. Global Blood Therapeutics (GBT) is traded on NASDAQ Exchange in USA and employs 457 people.

Management Performance

Global Blood Therapeutics Leadership Team

Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lesley Calhoun, Principal Accounting Officer, Vice President - Finance
Michael Bonney, Director
Stephanie Yao, IR Contact Officer
Myesha Lacy, IR Contact Officer
Mark Perry, Independent Director
Jeffrey Farrow, CFO
Myesha Edwards, IR Contact Officer
Philip Pizzo, Director
Glenn Pierce, Director
Willie Brown, Independent Director
Wendy Yarno, Director
Kevin Starr, Director
Hing Sham, Senior Vice President - Chemistry
Scott Morrison, Director
Deval Patrick, Independent Director
Tricia Suvari, Chief Legal Officer
Peter Radovich, Vice President - Program Leadership and Business Strategy
David Johnson, Chief Commercial Officer
Charles Homcy, Director
Dawn Svoronos, Director
Ted Love, President CEO, Director
Eleanor Ramos, Chief Medical Officer
John Schembri, Vice President of Finance and Administration
Jung Choi, Chief Business and Strategy Officer

Global Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Global Stock

If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
AI Investment Finder
Use AI to screen and filter profitable investment opportunities